Beta-blockers in the prevention and treatment of ischemic heart disease: Evidence and clinical practice

被引:5
|
作者
Khan, Omer [1 ]
Patel, Murti [1 ,2 ]
Tomdio, Anna N. [1 ,2 ]
Beall, Jeffrey [1 ]
Jovin, Ion S. [2 ,3 ]
机构
[1] Hunter Holmes McGuire VA Med Ctr, Dept Med, Richmond, VA USA
[2] Virginia Commonwealth Univ, Dept Med, Richmond, VA USA
[3] Virginia Commonwealth Univ, Hunter Holmes McGuire VA Med Ctr, Dept Med, 1201 Broad Rock Blvd Suite 4a-123, Richmond, VA 23249 USA
来源
HEART VIEWS | 2023年 / 24卷 / 01期
关键词
Acute coronary syndrome; beta-blocker; coronary artery disease; ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT-ELEVATION; PERCUTANEOUS CORONARY INTERVENTION; CHRONIC OBSTRUCTIVE PULMONARY; NONCARDIAC SURGERY; UNSTABLE ANGINA; TASK-FORCE; EUROPEAN-SOCIETY; ARTERY-DISEASE; CARDIAC EVENTS;
D O I
10.4103/heartviews.heartviews_75_22
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronary artery disease (CAD) is the most prevalent cardiovascular disease characterized by atherosclerotic plaque buildup that can lead to partial or full obstruction of blood flow in the coronary arteries. Treatment for CAD involves a combination of lifestyle changes, pharmacologic therapy, and modern revascularization procedures. Beta-adrenoceptor antagonists (or beta-blockers) have been widely used for decades as a key therapy for CAD. In this review, prior studies are examined to better understand beta-adrenoceptor antagonist use in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting. The evidence for the benefit of beta-blocker therapy is well established for patients with acute myocardial infarction, but it diminishes as the time from the index cardiac event elapses. The evidence for benefit in the perioperative setting is not strong.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 50 条
  • [41] Beta-blockers in heart failure
    Yudkin, J
    DIABETIC MEDICINE, 1999, 16 (09) : 785 - 787
  • [42] The role of beta-blockers in the treatment of chronic heart failure
    Kubon, Christer
    Mistry, Nisha B.
    Grundvold, Irene
    Halvorsen, Sigrun
    Kjeldsen, Sverre E.
    Westheim, Arne S.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (04) : 206 - 212
  • [43] Underuse of beta-blockers in Myocardial Infarction: the clinical practice against the scientific evidence.
    Leto, C
    Mancuso, G
    Russo, F
    Buccieri, M
    Vigna, L
    Musca, G
    Pujia, A
    ATHEROSCLEROSIS, 1999, 145 : S25 - S25
  • [44] Beta-blockers for coronary heart disease in chronic kidney disease
    Chonchol, Michel
    Benderly, Michal
    Goldbourt, Uri
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (07) : 2274 - 2279
  • [45] ISCHEMIC-HEART-DISEASE - HOW WELL ARE THE RISK PROFILES MODULATED BY CURRENT BETA-BLOCKERS
    LEREN, P
    CARDIOLOGY, 1993, 82 : 8 - 12
  • [46] THE CLINICAL USE OF BETA-BLOCKERS IN THE PREVENTION OF SUDDEN-DEATH
    COUMEL, P
    LECLERCQ, JF
    ZIMMERMAN, M
    EUROPEAN HEART JOURNAL, 1986, 7 : 187 - 201
  • [47] Primary prevention of cardiovascular disease endpoints using beta-blockers
    Michalewiz, L
    Chambers, R
    Grodzicki, T
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22): : 1759 - 1759
  • [49] Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension
    Staessen, JA
    Wang, JG
    Birkenhäger, WH
    Fagard, R
    EUROPEAN HEART JOURNAL, 1999, 20 (01) : 11 - 24
  • [50] TREATMENT AND PREVENTION OF MYOCARDIAL-INFARCTION - BETA-BLOCKERS IN THE NINETIES
    SCHREY, A
    PERFUSION, 1991, 4 (03): : 87 - 88